Acelyrin, INC 8-K filings

ACELYRIN, Inc. has completed its merger with Alumis Inc. on May 21, 2025, resulting in ACELYRIN becoming a wholly-owned subsidiary of Alumis.

ACELYRIN, INC. stockholders voted to approve the merger agreement with Alumis Inc. at a special meeting held on May 13, 2025.

ACELYRIN and Alumis have amended their merger agreement, increasing ACELYRIN stockholders' ownership in the combined company to approximately 48% on a fully diluted basis.

Acelyrin, a clinical biopharma company, adopts a limited-duration stockholder rights plan in response to Tang Capital Partners' increasing stake in the company.

Acelyrin and Alumis have agreed to merge in an all-stock transaction, aiming to create a leading late-stage clinical biopharmaceutical company focused on immune-mediated diseases.

Alumis and ACELYRIN will merge in an all-stock transaction to create a company with a late-stage clinical pipeline targeting immune-mediated diseases.

ACELYRIN, INC. has terminated its license and collaboration agreement with Affibody AB, effective 90 days after the notice date of January 31, 2025.

Acelyrin reported positive Phase 2 data for lonigutamab in thyroid eye disease, showing improvements across key metrics, and detailed the design of its Phase 3 program.

ACELYRIN, INC. reports the resignation of its CFO, disappointing results from a Phase 2b/3 trial for izokibep in uveitis, and a continued focus on its lonigutamab program for thyroid eye disease.

Acelyrin, Inc. has released financial details related to its acquisition of ValenzaBio, Inc., which closed on January 4, 2023, including audited financial statements for ValenzaBio and pro forma combined financials.

ACELYRIN announced its third quarter 2024 financial results, highlighted by a refocused pipeline strategy prioritizing lonigutamab for thyroid eye disease and upcoming milestones for both lonigutamab and izokibep.

Acelyrin is restructuring, suspending development of izokibep in certain indications, reducing its workforce by approximately one-third, and incurring significant restructuring charges.

Acelyrin will focus on its lonigutamab program for thyroid eye disease, while reporting positive Phase 3 results for izokibep in hidradenitis suppurativa and implementing a workforce reduction of approximately 33%.

Acelyrin, Inc. held its 2024 Annual Meeting of Stockholders on June 7, 2024, where directors were elected and the company's independent auditor was ratified.

Acelyrin has appointed Mina Kim as the new CEO, succeeding Shao-Lee Lin, and announced the departure of Chief People Officer Ron Oyston.

Acelyrin appoints a new CEO, provides updates on clinical trials for izokibep and lonigutamab, and reports a strong cash position of $678.5 million as of March 31, 2024.

ACELYRIN, INC. announced its full year 2023 financial results, highlighting positive clinical data for its drug candidates izokibep and lonigutamab, and a strong cash position to fund operations into 2026.

ACELYRIN's lonigutamab, a subcutaneous anti-IGF-1R antibody, demonstrated positive proof-of-concept data in a Phase 1/2 trial for thyroid eye disease, showing rapid improvements in key clinical measures.

ACELYRIN, INC. reported positive top-line results from its Phase 2b/3 clinical trial of izokibep in psoriatic arthritis and long-term data from its Phase 2b trial in hidradenitis suppurativa, demonstrating sustained responses and deepening clinical benefit.